...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Re: 50/50 at best on Zen being sold this year IMO..

you were whining about not knowing anything and not being able to sell your shares. I offerred you some thoughts and the possibility of a sale and now you want to set the terms of my offer and complain?  No problem, keep your shares and your misery and put me on ignore.

Share
New Message
Please login to post a reply